Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

90
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
90
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

769
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
769

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between prescribed hormonal contraception and multiple sclerosis risk: a systematic review and meta-analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Fatigue prevalence, interactions with associated symptoms and longitudinal changes in those with multiple sclerosis: Insights from the TONiC study.

Journal of the neurological sciences·2026
Same author

Employment status in people with multiple sclerosis: Profile, dynamic changes and determinants over time.

Multiple sclerosis and related disorders·2025
Same author

Therapeutic challenges in patients with multiple sclerosis and ankylosing spondylitis: A case series.

Multiple sclerosis and related disorders·2025
Same author

Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms.

Expert review of neurotherapeutics·2025
Same journal

Classifying Psychedelic-Related Complications.

Current topics in behavioral neurosciences·2026
Same journal

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.

Current topics in behavioral neurosciences·2026
Same journal

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Current topics in behavioral neurosciences·2025
Same journal

Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.

Current topics in behavioral neurosciences·2025
Same journal

Correction to: Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.

Current topics in behavioral neurosciences·2025
Same journal

Ontologically Challenging Psychedelic Experiences: Considerations for Managing Associated Distress.

Current topics in behavioral neurosciences·2025
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

28.0K

Helminth Therapy for MS.

Radu Tanasescu1,2,3, Cris S Constantinescu4

  • 1Division of Clinical Neuroscience, Clinical Neurology Research Group, University of Nottingham, Queen's Medical Centre, Nottingham, UK. R.Tanasescu@nottingham.ac.uk.

Current Topics in Behavioral Neurosciences
|December 5, 2014
PubMed
Summary
This summary is machine-generated.

Helminth therapy, using intestinal worms, is being explored to regulate the immune system and potentially treat multiple sclerosis (MS). This approach aims to manage autoimmune diseases by introducing controlled parasitic infections.

Keywords:
HelminthHygiene hypothesisImmunoregulationMultiple sclerosis

More Related Videos

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
12:40

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products

Published on: April 6, 2015

19.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

28.0K
Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
12:40

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products

Published on: April 6, 2015

19.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K

Area of Science:

  • Immunology
  • Neuroimmunology
  • Infectious Diseases

Background:

  • The hygiene hypothesis suggests environmental factors, like helminth infections, reduce autoimmunity prevalence globally.
  • Epidemiological data shows an inverse correlation between multiple sclerosis (MS) and helminth infections.
  • Helminths may act as immune regulators, evidenced by animal models and human observational studies in MS.

Purpose of the Study:

  • To review the rationale and current research status of helminth therapy for multiple sclerosis (MS).
  • To explore the potential of controlled parasitic infections as a treatment for MS and other autoimmune diseases.

Main Methods:

  • Review of existing data on helminth infections and their effects on immune-mediated diseases.
  • Focus on intestinal worms as a therapeutic strategy for autoimmune diseases, including MS.
  • Analysis of clinical trials investigating helminth therapy in MS patients.

Main Results:

  • Evidence from animal models and human studies suggests helminths possess immune-modulating properties beneficial for MS.
  • Helminth therapy aims for controlled parasitic introduction to prevent immune-mediated pathology without high parasite load risks.

Conclusions:

  • Helminth therapy is a promising, albeit developing, strategy for managing autoimmune diseases like MS.
  • Further research and clinical trials are crucial to establish the efficacy and safety of helminth therapy in MS.